Our research into anti-CD30 antibodies begins.
Our scientists synthesize monomethyl auristatin E (MMAE), the cytotoxic drug payload for our first investigational antibody–drug conjugate (ADC), brentuximab vedotin (ADCETRIS®).
2006
The first clinical trial patient receives brentuximab vedotin (ADCETRIS).
Seagen and Agensys (acquired by Astellas) enter into a collaboration, resulting in the co-development of enfortumab vedotin, an investigational ADC that targets Nectin-4.
Seagen and Takeda agree to globally co-develop and commercialize brentuximab vedotin (ADCETRIS).
2011
ADCETRIS® (brentuximab vedotin receives accelerated approval in the U.S.
Please see full Prescribing Information, including BOXED WARNING for PML, for ADCETRIS (brentuximab vedotin, for injection 50 mg).
Disease Area: Lymphoma
ADCETRIS is approved in the European Union.
Seagen expands access to ADC technology via collaborations with global biotechnology and pharmaceutical industry leaders.
2016
Our European headquarters opens in Zug, Switzerland.
ADCETRIS (brentuximab vedotin) receives approval for an additional indication in the U.S.
Please see full Prescribing Information, including BOXED WARNING for PML, for ADCETRIS (brentuximab vedotin, for injection 50 mg).
Disease Area: Lymphoma
2018
20-year anniversary of Seagen.
ADCETRIS (brentuximab vedotin) is approved in the U.S. for 2 additional indications.
Please see full Prescribing Information, including BOXED WARNING for PML, for ADCETRIS (brentuximab vedotin, for injection 50 mg).
Disease Area: Lymphoma
Seagen acquires Cascadian Therapeutics, including the late-stage investigational agent tucatinib.
2019
PADCEV® (enfortumab vedotin-ejfv) receives accelerated approval in the U.S.
Please see full Prescribing Information, including BOXED WARNING for Serious Skin Reactions, for PADCEV (enfortumab vedotin-ejfv, for injection 20 mg & 30 mg vials).
Disease Area: Urothelial Cancer
ADCETRIS is established as a foundation of care and approved in more than 70 countries.
2020
TUKYSA® (tucatinib,) is approved in the U.S. and other countries -- our third approved and first wholly-owned medicine.
Please see full Prescribing Information, for TUKYSA (tucatinib, 50 mg & 150 mg tablets)
Disease Area: Breast Cancer
Seattle Genetics, Inc. changes its name to Seagen Inc. to reflect the transformation of the company from its Seattle roots into a global operation.
TIVDAK® (tisotumab vedotin-tftv) receives accelerated approval in the U.S. – our fourth approved medicine.
Please see full Prescribing Information, including BOXED WARNING for Ocular Toxicity, for TIVDAK (tisotumabe vedotin-tftv, for injection 40 mg).
Disease Area: Cervical Cancer
Our commitment to innovation and making a meaningful impact in cancer care continues.